Alpha Teknova Inc. (TKNO) exhibits 33.2% gross margins and -21.3% return on invested capital within Health Care (Biotechnology: In Vitro & In Vivo Diagnostic Substances), balanced against a 24.0x enterprise multiple and 4.8% implied options volatility.
Sustained 33.2% gross profitability converts into -41.9% operating margin and -21.3% ROIC, outpacing sector cost of capital.
ROIC: -21.3% // GM: 33.2%YoY revenue trajectory of +7.4% paired with -1.96% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +7.4% // FCF YLD: -1.96%Altman Z-Score of 6.93 and Piotroski F-Score of 5/9 indicate low near-term refinancing stress.
ALTMAN Z: 6.93 // F-SCORE: 5/9Trading at 24.0x trailing P/E (— Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 24.0x // EV/EBITDA: —Options market prices a ±5.2% implied move with a 0.85 put/call ratio around $8.09 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: In Vitro & In Vivo Diagnostic Substances require continuous execution to defend -42.6% net margins.
NET MARGIN: -42.6% // D/E: 0.45x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for TKNO & activate live FRED threshold breach alerts.